2024
Cost-effectiveness of rapid vs in-house vs send-out ADAMTS13 testing for immune thrombotic thrombocytopenic purpura
Allen C, Ito S, Butt A, Purcell A, Richmond R, Tormey C, Krumholz H, Cuker A, Goshua G. Cost-effectiveness of rapid vs in-house vs send-out ADAMTS13 testing for immune thrombotic thrombocytopenic purpura. Blood Advances 2024, 8: 2279-2289. PMID: 38502197, PMCID: PMC11116991, DOI: 10.1182/bloodadvances.2024012608.Peer-Reviewed Original ResearchImmune thrombotic thrombocytopenic purpuraPLASMIC scoreThrombotic thrombocytopenic purpuraThrombocytopenic purpuraADAMTS13 testingIncremental net monetary benefitPer-patient cost savingsTherapeutic plasma exchangeBase-case analysisMarkov cohort simulationProbabilistic sensitivity analysesAmount of QALYEmpirical therapyADAMTS13 assaysPlasma exchangeEmpirical treatmentCaplacizumabFRET-based assayPrimary outcomePatientsNet monetary benefitCohort simulationCost-effectiveness evaluationPurpuraTesting strategies
2021
Incidence and associated factors of sudden unexpected death in advanced cancer patients: A multicenter prospective cohort study
Ito S, Morita T, Uneno Y, Taniyama T, Matsuda Y, Kohara H, Maeda I, Nakayama T, Mori M, Investigators T. Incidence and associated factors of sudden unexpected death in advanced cancer patients: A multicenter prospective cohort study. Cancer Medicine 2021, 10: 4939-4947. PMID: 34114364, PMCID: PMC8290229, DOI: 10.1002/cam4.4030.Peer-Reviewed Original ResearchConceptsInpatient hospices/palliative care unitsAdvanced cancer patientsProspective cohort studyCohort studyPalliative care physiciansCare unitCancer patientsFunctional status assessmentSudden unexpected deathOccurrence of sudden unexpected deathMulticenter prospective cohort studyFamily caregiversHospice/palliative careCare physiciansUnexpected deathMedical staffFunctional declineMale sexKarnofsky PSStatus assessmentPhysiciansSudden deathDeathIncidencePatients